PARIS (March 15, 2017) - International law firm McDermott Will & Emery advised French pharmaceutical laboratory Servier on its partnership with Neurochlore to develop and market bumetanide in pediatric autism in Europe. 

The terms of the agreement state that Servier will develop and market the product in Europe while Neurochlore will retain these rights for the United States. Rights in relation to other countries are still under negotiation. The development plan includes three Phase 3 trials with an oral liquid form designed for children. Filing for marketing authorization is envisaged for the end of 2021.

The McDermott team advising on this transaction was led by a Paris-based partner Emmanuelle Trombe and associate Anne-France Moreau. Neurochlore was represented by Luc Barny.

McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.